Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

lncRNA - Long Non-coding RNAs02:39

lncRNA - Long Non-coding RNAs

9.7K
In humans, more than 80% of the genome gets transcribed. However, only around 2% of the genome codes for proteins. The remaining part produces non-coding RNAs which includes ribosomal RNAs, transfer RNAs, telomerase RNAs, and regulatory RNAs, among other types. A large number of regulatory non-coding RNAs have been classified into two groups depending upon their length – small non-coding RNAs, such as microRNA, which are less than 200 nucleotides in length, and long non-coding RNA...
9.7K
lncRNA - Long Non-coding RNAs02:39

lncRNA - Long Non-coding RNAs

3.4K
3.4K
Experimental RNAi02:15

Experimental RNAi

7.2K
RNA interference (RNAi) is a cellular mechanism that inhibits gene expression by suppressing its transcription or activating the RNA degradation process. The mechanism was discovered by Andrew Fire and Craig Mello in 1998 in plants. Today, it is observed in almost all eukaryotes, including protozoa, flies, nematodes, insects, parasites, and mammals. This precise cellular mechanism of gene silencing has been developed into a technique that provides an efficient way to identify and determine the...
7.2K
RNA Interference01:23

RNA Interference

27.6K
RNA interference (RNAi) is a process in which a small non-coding RNA molecule blocks the post-transcriptional expression of a gene by binding to its messenger RNA (mRNA) and preventing the protein from being translated.
This process occurs naturally in cells, often through the activity of genomically-encoded microRNAs. Researchers can take advantage of this mechanism by introducing synthetic RNAs to deactivate specific genes for research or therapeutic purposes. For example, RNAi could be used...
27.6K
NF-κB-dependent Signaling Pathway02:26

NF-κB-dependent Signaling Pathway

9.7K
The transcription factor NF-κB was discovered in 1986 in the lab of Nobel laureate Professor David Baltimore, for its interaction with the immunoglobulin light chain enhancer in B-cells. After more than three decades of study, it is now evident that NF-κB regulates the expression of over 100 genes. Most of these genes play an essential role in the innate and adaptive immune responses as well as the inflammatory responses of animals.
NF-κB-dependent Signaling Mechanism
The...
9.7K
Types of RNA01:20

Types of RNA

8.7K
Three main types of RNA are involved in protein synthesis: messenger RNA (mRNA), transfer RNA (tRNA), and ribosomal RNA (rRNA). These RNAs perform diverse functions and can be broadly classified as protein-coding or non-coding RNA. Non-coding RNAs play important roles in regulating gene expression in response to developmental and environmental changes. Non-coding RNAs in prokaryotes can be manipulated to develop more effective antibacterial drugs for human or animal use.
RNA Performs Diverse...
8.7K

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Discovery and therapeutic delivery of microRNAs targeting deregulated glioblastoma pathways inhibits tumor growth in mice.

The Journal of clinical investigation·2026
Same author

Identification of genes associated with smell dysfunction in Parkinson's disease.

Clinical parkinsonism & related disorders·2026
Same author

Microenvironment T-Type calcium channels regulate neuronal and glial processes in tumor cells to promote glioblastoma growth.

Neuro-oncology·2026
Same author

PATTY corrects open-chromatin bias for improved bulk and single-cell CUT&Tag profiling.

Nature communications·2026
Same author

Real world experience with cyclin dependent kinase inhibitors in metastatic breast cancer in India.

PloS one·2026
Same author

Increased expression of a subset of genes within reduced copy number regions across multiple cancer types.

bioRxiv : the preprint server for biology·2026
Same journal

CDK2 Inhibition Exerts RB-Independent Antitumor Activity in CDK4/6 Inhibitor-Resistant HR+/HER2- Breast Cancer.

Cancer research·2026
Same journal

A Clinically Integrated Pediatric Patient-Derived Xenograft Program Enables Evaluation of Cohort and Patient-Specific Biology and Therapeutic Strategies.

Cancer research·2026
Same journal

Editor's Note: Heterodimerization of Insulin-like Growth Factor Receptor/Epidermal Growth Factor Receptor and Induction of Survivin Expression Counteract the Antitumor Action of Erlotinib.

Cancer research·2026
Same journal

Editor's Note: Deguelin Analogue SH-1242 Inhibits Hsp90 Activity and Exerts Potent Anticancer Efficacy with Limited Neurotoxicity.

Cancer research·2026
Same journal

Retraction: Two Functional Epitopes of Pigment Epithelial-Derived Factor Block Angiogenesis and Induce Differentiation in Prostate Cancer.

Cancer research·2026
Same journal

Editor's Note: Chronic Stress Facilitates Lung Tumorigenesis by Promoting Exocytosis of IGF2 in Lung Epithelial Cells.

Cancer research·2026
See all related articles

Related Experiment Video

Updated: Dec 31, 2025

Dual CRISPR-Interference Strategy for Targeting Synthetic Lethal Interactions Between Non-Coding RNAs in Cancer Cells
07:23

Dual CRISPR-Interference Strategy for Targeting Synthetic Lethal Interactions Between Non-Coding RNAs in Cancer Cells

Published on: May 30, 2025

1.0K

Long Noncoding RNA DRAIC Inhibits Prostate Cancer Progression by Interacting with IKK to Inhibit NF-κB Activation.

Shekhar Saha1, Manjari Kiran1, Canan Kuscu1

  • 1Department of Biochemistry and Molecular Genetics, University of Virginia School of Medicine, Charlottesville, Virginia.

Cancer Research
|January 5, 2020
PubMed
Summary
This summary is machine-generated.

The long noncoding RNA DRAIC suppresses prostate cancer progression by inhibiting the NF-κB pathway. Reduced DRAIC levels correlate with increased tumor aggressiveness and poor patient outcomes in multiple cancers.

More Related Videos

Sequencing Small Non-coding RNA from Formalin-fixed Tissues and Serum-derived Exosomes from Castration-resistant Prostate Cancer Patients
12:13

Sequencing Small Non-coding RNA from Formalin-fixed Tissues and Serum-derived Exosomes from Castration-resistant Prostate Cancer Patients

Published on: November 19, 2019

7.1K
miRNA Expression Analyses in Prostate Cancer Clinical Tissues
11:29

miRNA Expression Analyses in Prostate Cancer Clinical Tissues

Published on: September 8, 2015

11.2K

Related Experiment Videos

Last Updated: Dec 31, 2025

Dual CRISPR-Interference Strategy for Targeting Synthetic Lethal Interactions Between Non-Coding RNAs in Cancer Cells
07:23

Dual CRISPR-Interference Strategy for Targeting Synthetic Lethal Interactions Between Non-Coding RNAs in Cancer Cells

Published on: May 30, 2025

1.0K
Sequencing Small Non-coding RNA from Formalin-fixed Tissues and Serum-derived Exosomes from Castration-resistant Prostate Cancer Patients
12:13

Sequencing Small Non-coding RNA from Formalin-fixed Tissues and Serum-derived Exosomes from Castration-resistant Prostate Cancer Patients

Published on: November 19, 2019

7.1K
miRNA Expression Analyses in Prostate Cancer Clinical Tissues
11:29

miRNA Expression Analyses in Prostate Cancer Clinical Tissues

Published on: September 8, 2015

11.2K

Area of Science:

  • Oncology
  • Molecular Biology
  • Genetics

Background:

  • Prostate cancer, particularly castration-resistant advanced prostate cancer, is a significant health concern.
  • Long noncoding RNAs (lncRNAs) are increasingly recognized for their roles in cancer development and progression.
  • The lncRNA DRAIC is downregulated in castration-resistant prostate cancer and its decreased expression is linked to poor patient outcomes.

Purpose of the Study:

  • To investigate the functional role of DRAIC in prostate cancer progression.
  • To elucidate the molecular mechanisms by which DRAIC regulates cancer cell behavior.
  • To determine the relationship between DRAIC expression and the NF-κB signaling pathway.

Main Methods:

  • Quantitative real-time PCR to assess DRAIC expression levels.
  • Cell invasion assays and soft agar colony formation assays to evaluate cancer cell aggressiveness.
  • Western blotting to analyze the activation status of the NF-κB pathway components.
  • RNA-binding assays and co-immunoprecipitation to study the interaction of DRAIC with the IκB kinase (IKK) complex.

Main Results:

  • Decreased DRAIC expression in prostate cancer correlates with increased expression of NF-κB target genes.
  • Downregulation of DRAIC enhances cancer cell invasion and colony formation, a process dependent on NF-κB activation.
  • DRAIC directly interacts with the IKK complex, inhibiting IκBα phosphorylation and subsequent NF-κB activation.
  • The tumor-suppressive function of DRAIC is mapped to a specific region (bases 701-905).

Conclusions:

  • DRAIC acts as a tumor suppressor in prostate cancer by inhibiting the NF-κB signaling pathway.
  • DRAIC suppresses cancer progression by interfering with IKK activity, thereby preventing NF-κB activation.
  • Restoring DRAIC expression may represent a potential therapeutic strategy for prostate cancer.